Clinical Trial Update: An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GSK2269557 added to standard care in acute exacerbation of chronic obstructive pulmonary disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK2269557

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2017-03-09